Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Wolfsberg – page 3

78 clinical trials in Wolfsberg, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Wolfsberg at a glance
78
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

78 trials in Wolfsberg

Open in trial search

A Study of MK-1084 and Drug Combination Versus Pembrolizumab and Chemotherapy for Adults with Advanced Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study on Atezolizumab and Bevacizumab for Patients with Intermediate-Stage Liver Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Study on Fazirsiran for Patients with Alpha-1 Antitrypsin Deficiency Liver Disease and Mild Fibrosis

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Fazirsiran
  • Sponsor:Takeda Development Center Americas Inc.

Pneumonia

Recruiting

Study of Trimodulin for Adults Hospitalized with Severe Community-Acquired Pneumonia

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Trimodulin (Human Igm, Iga, Igg Solution)
  • Sponsor:Biotest GmbH & Co. KGaA

Study on Fazirsiran for Patients with Alpha-1 Antitrypsin Deficiency-Related Liver Disease and Fibrosis

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Fazirsiran
  • Sponsor:Takeda Development Center Americas Inc.

Atrial fibrillation

Not yet recruiting

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.

Aortic valve stenosis

Not yet recruiting

A Phase 2b/3 Randomized Double‑Blind Study of Ataciguat to Slow Disease Progression in Adults with Moderate Calcific Aortic Valve Stenosis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ataciguat
  • Sponsor:Kardigan Inc.

Safety and efficacy of efimosfermin alfa versus placebo in adults with compensated cirrhosis (stage F4) due to MASH

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Study of efimosfermin alfa versus placebo in adults with compensated cirrhosis from metabolic dysfunction-associated steatohepatitis (MASH)

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Pulmonary hypertension

Not yet recruiting

A study to evaluate the effectiveness of levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction.

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Levosimendan
  • Sponsor:Tenax Therapeutics Inc.

Comparison of dupilumab and tezepelumab for the treatment of chronic rhinosinusitis with nasal polyps.

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Medical University Of Vienna

Hypertrophic cardiomyopathy

Not yet recruiting

Study on Mavacamten for Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Mavacamten
  • Sponsor:Myokardia Inc.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Wolfsberg

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical trials focusing on hormone receptor-positive breast cancer treatment optimization. The research explores enhanced therapeutic approaches for patients with HER2-negative early breast cancer.

  • Treatment Enhancement Studies
  • Endocrine Therapy Research
  • Disease-Free Survival Analysis

Current investigations evaluate the effectiveness of combining standard endocrine therapy with novel therapeutic agents to improve patient outcomes in early-stage breast cancer treatment.

02 Oncology Therapeutics

Advanced research examining the potential of combination therapy approaches in breast cancer treatment. Studies focus on evaluating long-term treatment strategies spanning multiple years.

  • Combination Treatment Protocols
  • Long-term Therapeutic Outcomes
  • Invasive Disease Management

The research aims to establish more effective treatment protocols for patients with hormone-sensitive breast cancer through innovative therapeutic combinations.

03 Clinical Outcomes Research

Comprehensive studies analyzing invasive disease-free survival in breast cancer patients. The research evaluates the impact of enhanced treatment protocols on patient outcomes.

  • Survival Rate Analysis
  • Treatment Response Assessment
  • Long-term Patient Monitoring

These trials focus on gathering crucial data about treatment effectiveness and patient response in early-stage breast cancer management.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.